Kinetics of PBPC mobilization by cyclophosphamide, as compared with that by epirubicin/paclitaxel followed by G-CSF support: Implications for optimal timing of PBPC harvest

Transfusion

Volumn 41, Issue 5, 2001, Pages 681-686

  Dettke, Markus ^a   Greinix, Hildegard T ^a   Kalhs, Peter ^a   Kührer, Irene ^a   Worel, Nina ^a   Höcker, Paul ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; CYCLOPHOSPHAMIDE; EPIRUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL;

ADULT; AGED; APHERESIS; ARTICLE; AUTOTRANSPLANTATION; BLOOD VOLUME; BREAST CANCER; CANCER STAGING; CELL CULTURE; CELL KINETICS; CELL MOTILITY; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FLOW CYTOMETRY; HUMAN; LEUKAPHERESIS; MAJOR CLINICAL STUDY; STEM CELL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD VOLUME; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; EPIRUBICIN; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; LEUKAPHERESIS; LEUKOCYTE COUNT; MALE; MIDDLE AGED; PACLITAXEL; TIME FACTORS;

EID: 0034839849     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1537-2995.2001.41050681.x     Document Type: Article

References (32)

1. Blood and marrow transplantation activity in Europe 1997
2. Peripheral blood stem cell mobilization for high-dose chemotherapy
3. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy
4. Clinical relevance of CD34+ cell measurement in PBSC transplantation
5. + cell counts decrease hematologic toxicity of autologous peripheral blood progenitor cell transplantation
6. Tandem and triple high-dose chemotherapy with autologous stem cell rescue in metastatic breast cancer
7. Tumour cell detection in G-CSF mobilised stem cell harvests of patients with breast cancer
8. High-dose chemotherapy in patients with breast cancer: Evaluation of infusing peripheral blood stem cells containing occult tumor cells
9. Conventionaldose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer
10. Improved priming of mobilization of and optimal timing for harvest of peripheral blood stem cells
11. Mobilization of peripheral blood progenitor cells after induction chemotherapy (THP-doxorubicin-vinorelbine-cyclophospha-mide-fluorouracil) and granulocyte colony-stimulating factor in breast cancer
12. Correlation between granulocyte/macrophage-colony-forming units and CD34+ cells in apheresis products from patients treated with different chemotherapy regimens and granulocyte-colony-stimulating factor to mobilize peripheral blood progenitor cells
13. Effect of different chemotherapy regimens on peripheral blood stem cell collections in patients with breast cancer receiving granulocyte colony-stimulating factor
14. A phase I study of paclitaxel for mobilization of peripheral blood progenitor cells
15. Collection of circulating progenitor cells after epirubicin, paclitaxel and filgrastim in patients with metastatic breast cancer
16. Mobilization, collection, and characterization of peripheral blood hematopoietic progenitors after chemotherapy with epirubicin, paclitaxel, and granulocyte-colony stimulating factor administered to patients with metastatic breast carcinoma
17. The ISHAGE guidelines for CD34 cell determination by flow cytometry
18. When to harvest peripheral-blood stem cells after mobilization therapy: Prediction of CD34-positive cell yield by preceeding day CD34-positive concentration in peripheral blood
19. The predictive value of white cell or CD34+ cell count in the peripheral blood for timing apheresis and maximizing yield
20. Isolation of CD34+ progenitor cells from peripheral blood by use of an automated immunomagnetic selection system: Factors affecting the results
21. Complications of peripheral blood stem cell harvesting: Review of 554 PBSC leukaphereses
22. Adverse events occuring during bone marrow peripheral blood progenitor cell infusion: Analysis of 126 cases
23. Adverse reactions in patients transfused with cryopreserved marrow
24. CD34+ cells mobilized by cyclophosphamide and granulocyte colony-stimulating factor (G-CSF) are functionally different from CD34+ cells mobilized by G-CSF
25. Correlation between granulocyte/macrophage-colony-forming units and CD34+ cells in apheresis products from patients treated with different chemotherapy regimens and granulocyte-colony-stimulating factor to mobilize peripheral blood progenitor cells
26. Endogenous interleukin-8 (IL-8) surge in granulocyte colony-stimulating factor-induced peripheral blood stem cell mobilization
27. Mobilization and homing of peripheral blood progenitors is related to reversible downregulation of α4 β1 integrin expression and function
28. Factors that influence collection and engraftment of autologous peripheral-blood stem cells
29. Collection of peripheral blood progenitor cells for autografting with low-dose cyclophosphamide plus granulocyte colony-stimulating factor
30. Guidelines for autologous blood and marrow stem cell transplantation in multiple sclerosis: A consensus report written on behalf of the European Group for Blood and Marrow Transplantation and the European Charcot Foundation
31. Large-volume apheresis for the harvest of peripheral blood progenitor cells for autologous transplantation
32. A prospective, randomized, sequential, crossover trial of large-volume versus normal-volume leukapheresis procedures: Effects on progenitor cells and engraftment